1. Lilly and Metastatic Breast Cancer Advocates Reports RWE and Launches 'Thriver Movement’ #MoreforMBC

Published: 10 Oct, 2018 | Tags: Lilly; Metastatic Breast Cancer Advocates, Reports, RWE, Launches, ‘Thriver Movement’, #MoreforMBC  

2. Sandoz Signs a Non-Exclusive License Agreement with AbbVie for IPR of its Humira (adalimumab) for Major EU Countries

Published: 11 Oct, 2018 |Tags: Sandoz, Signs, Non-Exclusive License, Agreement, AbbVie, IPR,  Humira (adalimumab), EU Countries  

3. Myriad and Pfizer Signs a Service Agreement for Testing of BRCA-Mutated Triple Negative Breast Cancer

Published: 10 Oct, 2018 | Tags: Myriad, Pfizer, Signs, Service Agreement, Testing, BRCA-Mutated Triple Negative Breast Cancer, Talazoparib  

4. MundiPharama Acquires Cinfa Biotech for Expansion of its Biosimilar Portfolio

Published: 10 Oct, 2018 | Tags: Mundipharma, Acquires, Cinfa Biotech, Expansion, Biosimilar, Portfolio, Pelmeg, pegfilgrastim  

5. Celgene to Present Results of Two P-III Trial SUNBEAM and RADIANCE Part B for Ozanimod to Treat RMS at ECTRIMS 2018

Published: 10 Oct, 2018 | Tags: Celgene, Present, Results, Two P-III Trial, SUNBEAM, RADIANCE Part B, Ozanimod, Treat, RMS, ECTRIMS 2018  

6. Konan Medical Receives FDA 510(k) Approval for its objectiveFIELD Device

Published: 10 Oct, 2018 | Tags: Konan Medical, Receives, FDA 510(k), Approval, objectiveFIELD Device, (mfPOP) Technology  

7. Roche and Ionis Collaborates to Develop Ionis’s IONIS-FB-LRx to Treat Complement-Mediated Diseases for $760M

Published: 10 Oct, 2018 | Tags: Roche, Ionis, Collaborates, Develop, IONIS-FB-LRx,Treat, Complement-Mediated Diseases, $760M  

8. Celltrion and Teva Announces Approval Recommendations for CT-P10’s (rituximab, biosimilar) BLA from the US FDA’s ODAC

Published: 10 Oct, 2018 | Tags: Celltrion, Teva, Announces, Approval, Recommendations, CT-P10’s (rituximab, biosimilar), BLA the US FDA’s ODAC  

9. Novartis Reports Results of P-IIIb ASSESS study for Gilenya (fingolimod) vs Copaxone (glatiramer acetate)

Published: 10 Oct, 2018 | Tags: Novartis, Reports, Results , P-IIIb, ASSESS study, Gilenya (fingolimod) ,  Copaxone (glatiramer acetate)  

10. Eli Lily and Boehringer Ingelheim’s (BI) Jardiance (empagliflozin) Shows to Increase Life Span in Adults with T2D and Cardiovascular Disorders

Published: 10 Oct, 2018 | Tags: Eli Lily, Boehringer Ingelheim, Jardiance (empagliflozin), Shows, Increment, Life Span, Adults, T2D, Cardiovascular Disorders, EMPA-REG OUTCOME  

11. MeiraGTx Acquires Vector Neurosciences to Strengthen its Neurology Portfolio

Published: 9 Oct, 2018 | Tags: MeiraGTx, Acquisition, Vector Neurosciences, Strengthen, Neurology Platform  

12. Therachon Acquires GLyPharma Therapeutic to Expand its Rare Disease Portfolio

Published: 9 Oct, 2018 | Tags: Therachon, Acquires, GLyPharma, Therapeutic, Expand, Rare Disease Portfolio  

13. Novartis Reports Positive Results of P-II SUSTAIN study for Crizanlizumab (SEG101) to Treat Sickle Cell Disease (SCD)

Published: 9 Oct, 2108 | Tags: Novartis, Reports, Results, P-II SUSTAIN study, Crizanlizumab (SEG101), Treatment, Sickle Cell Disease (SCD)  

14. Roche to Present Results of P-III Trial for Ocrevus (ocrelizumab) at ECTRIMS 2018

Published: 10 Oct, 2108 | Tags: Roche, Present, Results, P-III Trial, Ocrevus (ocrelizumab), ECTRIMS 2018, OPERA I, OPERA II and ORATORIO  

15. MVP and Daiichi Signs Exclusive Distribution and License Agreement for Penthrox in China, Thailand, Vietnam

Published: 8 Oct, 2108 | Tags: MVP, Daiichi, Signs, Exclusive, Distribution, License Agreement, Penthrox, China, Thailand, Vietnam  

16. Roche to Present Positive Results of Cancer Immunotherapy Programmes at ESCO 2018

Published: 9 Oct, 2018 | Tags: Roche, Present, Positive Results, Cancer, Immunotherapy Programmes, ESCO 2018, P-III ALESIA, P-III IMpower130 study  

17. Celgene Reports Otezla (apremilast) Achieve 1EP in P-III STYLE study to Treat Moderate-to-Severe Scalp Psoriasis

Published: 8 Oct, 2108 | Tags: Celgene, Reports, Otezla (apremilast), Achieve, 1EP, P-III STYLE study, Treat, Moderate-to-Severe Scalp Psoriasis  

18. Regeneron to Present Results of Libtayo (cemiplimab) for Six Tumor Indications at ESMO 2018

Published: 8 Oct, 2108 | Tags: Regeneron, Present, Results, Libtayo (cemiplimab), Six, Tumor Indications, ESMO 2018, CSCC, mCSCC, the US FDA  

19. Merck’s Gardasil 9 Receives FDA’s Expanded Label Approval for Prevention of HPV Related Disorders

Published: 5 Oct, 2018 | Tags: Merck, Gardasil 9, Receives, FDA, Expanded Label Approval, Prevention, HPV Related Disorders  

20. AbbVie’s Orilissa (elagolix) Receives Health Canada Approval to Treat Moderate-to-Severe Pain Associated with Endometriosis

Published: 5 Oct, 2018 | Tags: AbbVie, Orilissa (elagolix), Receives, Health Canada, Approval, Moderate-to-Severe Pain, Endometriosis, P-III study  

21. Novartis Announces Acceptance of its Novel Siponimod (BAF312) by the US FDA and EMA

Published: 8 Oct, 2018 | Tags: Novartis, Announces, Acceptance, Novel, Siponimod (BAF312) , the US FDA ,EMA ,NDA, MAA, Regulatory